ATE398449T1 - Verwendung von azetidincarboxamidderivaten in therapie - Google Patents

Verwendung von azetidincarboxamidderivaten in therapie

Info

Publication number
ATE398449T1
ATE398449T1 AT04730286T AT04730286T ATE398449T1 AT E398449 T1 ATE398449 T1 AT E398449T1 AT 04730286 T AT04730286 T AT 04730286T AT 04730286 T AT04730286 T AT 04730286T AT E398449 T1 ATE398449 T1 AT E398449T1
Authority
AT
Austria
Prior art keywords
sup
therapy
carboxamide derivatives
azetidine carboxamide
aryl
Prior art date
Application number
AT04730286T
Other languages
German (de)
English (en)
Inventor
James E P Davidson
David R Adams
Michael J Bickerdike
Allan Fletcher
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE398449T1 publication Critical patent/ATE398449T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04730286T 2003-05-01 2004-04-29 Verwendung von azetidincarboxamidderivaten in therapie ATE398449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0310057 2003-05-01

Publications (1)

Publication Number Publication Date
ATE398449T1 true ATE398449T1 (de) 2008-07-15

Family

ID=33397042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730286T ATE398449T1 (de) 2003-05-01 2004-04-29 Verwendung von azetidincarboxamidderivaten in therapie

Country Status (16)

Country Link
US (1) US20060276452A1 (https=)
EP (1) EP1617839B1 (https=)
JP (1) JP2006525297A (https=)
KR (1) KR20060017763A (https=)
CN (1) CN1780615A (https=)
AT (1) ATE398449T1 (https=)
AU (1) AU2004233644A1 (https=)
BR (1) BRPI0409959A (https=)
CA (1) CA2524245A1 (https=)
DE (1) DE602004014484D1 (https=)
EA (1) EA200501703A1 (https=)
MX (1) MXPA05011472A (https=)
NO (1) NO20055655L (https=)
NZ (1) NZ543322A (https=)
WO (1) WO2004096209A1 (https=)
ZA (1) ZA200508835B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004234125A1 (en) * 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
US20090221644A1 (en) * 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
US20090264470A1 (en) * 2006-02-21 2009-10-22 Bennett Teresa A CB1 Antagonists and Inverse Agonists
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US11141404B1 (en) 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
AU2022362107A1 (en) * 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPH03264562A (ja) * 1989-05-22 1991-11-25 Hokuriku Seiyaku Co Ltd ピペリジン誘導体
JP3194355B2 (ja) * 1996-10-24 2001-07-30 宇部興産株式会社 ピペリジン化合物及びその製法
WO1999037612A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders
GB9917386D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-II
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
AU2004234125A1 (en) * 2003-05-01 2004-11-11 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders

Also Published As

Publication number Publication date
NO20055655L (no) 2006-01-31
CA2524245A1 (en) 2004-11-11
EP1617839A1 (en) 2006-01-25
NO20055655D0 (no) 2005-11-30
JP2006525297A (ja) 2006-11-09
US20060276452A1 (en) 2006-12-07
NZ543322A (en) 2009-03-31
AU2004233644A1 (en) 2004-11-11
ZA200508835B (en) 2006-12-27
BRPI0409959A (pt) 2006-04-25
CN1780615A (zh) 2006-05-31
EA200501703A1 (ru) 2006-06-30
DE602004014484D1 (de) 2008-07-31
EP1617839B1 (en) 2008-06-18
KR20060017763A (ko) 2006-02-27
MXPA05011472A (es) 2005-12-12
WO2004096209A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
ATE398449T1 (de) Verwendung von azetidincarboxamidderivaten in therapie
ATE453620T1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
NZ528851A (en) N-aroyl cyclic amines
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
ATE440603T1 (de) 8-hydroxychinolinderivate
JO2282B1 (en) Oxazole derivatives
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
ATE384058T1 (de) Thiazolderivate
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten
SE9902267D0 (sv) New compounds
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
BRPI0517734A (pt) derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina
DE69911373D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
ATE220665T1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
BG105469A (en) Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
AU2003288107A1 (en) Tiotropium-containing medicament combinations used for inhaling
TW200511994A (en) Novel compounds and therapeutic uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties